Nanobiotix S.A. (NBTX) AI Stock Analysis

Nanobiotix S.A., headquartered in Paris, France, is an innovative clinical-stage biotechnology company established in 2003 that specializes in developing cancer therapies. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles engineered to improve oncological treatment outcomes. NBTXR3 is designed for several cancer types, including soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancers. The company has also entered into a strategic collaboration with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand.

Over a five-year period from FY2020 to FY2025, Nanobiotix posted a revenue CAGR of 66.4%. Revenue fluctuated significantly, moving from $2.6M in FY2021 to $36.2M in FY2023, before turning to -$7.2M in FY2024 and recovering to $29.6M in FY2025. Across all reported fiscal years, the gross margin remained at 100.0%. However, the company has consistently generated net losses, recording -$24.0M in FY2025 and -$68.1M in FY2024. For the latest quarter ending June 30, 2026, quarterly revenue growth declined 79.2% year-over-year, leading to a trailing twelve-month revenue of $11.5M and an operating margin of -322.9%.

As of June 30, 2026, Nanobiotix held $110.8M in cash and short-term investments alongside total debt of $106.6M, resulting in net cash of $4.3M. Total assets stood at $128.3M, and the current ratio was 1.44. The company reported negative shareholders' equity of -$33.4M. Cash burn has been sustained, with FY2025 operating cash flow of -$33.4M and free cash flow of -$34.0M. Capital expenditures in FY2025 totaled $546,000, while the five-year share count increased by 40.4%.

Nanobiotix trades at a forward P/E of 42.4x and a price-to-sales ratio of 94.3x, compared to the median of its US-listed Healthcare peers of 17.3x forward P/E and 4.1x price-to-sales. Its enterprise value to revenue multiple is 53.4x. The stock closed at $21.30 on October 16, 2026, sitting 36.3% below its 200-day moving average. Over the past year, the stock dropped 19.8%, trailing the S&P 500 (SPY) gain of 16.8%, though its 5-year return of 66.1% compares against the S&P 500's 83.0%.

Wall Street analysts currently assign Nanobiotix 4 Strong Buy ratings and 1 Hold rating, with no Sell or Buy ratings. The mean price target is $54.03, reflecting a 153.7% premium over the last close of $21.30. For the current fiscal year ending December 31, 2026, consensus estimates project an EPS of -$0.54 on revenue of $29.4M. For the next fiscal year, analysts forecast revenue to expand 50.7% to $44.4M with an EPS of -$0.15. The company beat EPS estimates in 2 of the last 4 quarters.

This page is an AI-written research summary of Nanobiotix S.A. (NBTX). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: NBTX income statement, NBTX balance sheet, NBTX key metrics, NBTX analyst forecast, NBTX chart. See the NBTX stock overview for the latest quote and news.